2:28
ESH AL 2018 | Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser
1:38
ESH AL 2018 | Challenges with the identification of ALL subtypes
Charles Mullighan
2:24
ESH AL 2018 | Current understandings of ALL approaches
Charles Mullighan
1:19
ASH 2017 | Myeloma XI trial: impact of MRD on treatment response in MM
Graham Jackson
1:34
ASH 2017 | Multiple myeloma highlights at ASH 2017
Graham Jackson
2:19
ASH 2017 | ASH 2017: CLL combination therapy highlights
Arnon Kater
3:12
ASH 2017 | Results of the MURANO study for CLL
Arnon Kater
1:18
ASH 2017 | ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst
1:10
ASH 2017 | Impacts of the MURANO study for future CLL treatment
Barbara Eichhorst
2:38
ASH 2017 | “Sequential triple-T” therapy for CLL
Barbara Eichhorst
2:19
ASH 2017 | Bendamustine plus rituximab vs. standard therapy for advanced CLL
Barbara Eichhorst
1:48
ASH 2017 | Novel CLL therapy highlights from ASH 2017
Anthony Mato
1:13
ASH 2017 | Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:21
ASH 2017 | Triple therapy for CLL: pembrolizumab, ublituximab and umbralisib
Anthony Mato
3:36
ASH 2017 | Retrospective multicenter analysis of venetoclax-treated CLL patients
Anthony Mato
1:38
ASH 2017 | Front-line use of ibrutinib for CLL in a real-world setting
Anthony Mato
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals